Novel Algorithm Addresses Challenges in Immunotherapy

Laurie Toich, Assistant Editor
Published Online: Monday, November 27th, 2017
A newly-developed mathematical model may be able to accurately predict whether a patient with cancer will respond to immunotherapy, according to a study published in Nature

Immunotherapies are promising new cancer treatments that tend to be less toxic than traditional therapies. However, patients may not always respond to therapy or they may experience significant adverse events.

Scientists have been searching for a way to determine whether patients will respond to new checkpoint inhibitors and to understand the characteristics underlying why the therapy was successful.

 
The novel algorithm characterizes the tumor's evolution and its interactions with the immune system, according to the study. The authors said that this mathematical algorithm can more accurately predict how cancer will respond to immunotherapy compared with currently used biomarkers.
 
"We present an interdisciplinary approach to studying immunotherapy and immune surveillance of tumors," said senior author Benjamin Greenbaum, PhD. "This approach will hopefully lead to better mechanistic predictive modeling of response and future design of therapies that further take advantage of how the immune system recognizes tumors."
 
The model may also help discover new therapies that can target the immune system or vaccines for patients who do not respond to immunotherapy, according to the study.
 
Data from patients with melanoma and lung cancer who received immunotherapy treatment were compiled to create the model. The system can track immune response to the drugs by focusing on neoantigens.
 
The authors note that neoantigens have the potential to be an immunotherapy target and can be useful for patients with drug resistant disease. The neoantigens may be critical to understanding why sometimes immunotherapy results in autoimmune side effects, according to the authors.
 
Specifically, the mathematical model can predict immune response in patients with pancreatic cancer.
 
These models may result in more accurate therapy and prevent potentially dangerous adverse events. Additionally, it could reduce drug costs, as the model could prevent unnecessary treatments, according to the authors. 
 
"This research represents a big step forward in understanding why some tumors are more aggressive than others and being able to predict rationally which neoantigens will be the most effective at stimulating an immune response," said corresponding author Vinod P. Balachandran, MD.

This article originally appeared on Specialty Pharmacy Times


Current Issue

The Educated Patient

Sara Marlow, MSN, RN, PHN, FNP-C
Sunburn is still a major health issue that can be prevented.
Kristen Marjama, DNP, FNP-BC
The National Health Interview Survey in 2014 estimated that 17.7 million adults and 6.3 million children had asthma.
Mary McCormack, MSN, APNC, MPH
The World Gastroenterology Organization describes the prevalence of celiac disease as a “statistical iceberg” in today’s health climate.
Melissa DeCapua, DNP, PMHNP-B-C
Diabetic retinopathy causes more losses of vision worldwide than any other eye disease, affecting 33% of the 285 million individuals suffering from diabetes.
$vacMongoViewPlus$ $vAR$
Contemporary Clinic
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
ONCLive
OTCGuide
Pharmacy Times
Specialty Pharmacy Times
Targeted Oncology
About Us
Advertise
Careers
Contact Us
Feedback
Privacy
Terms & Conditions
Pharmacy Healthcare & Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-257-0701

Copyright Contemporary Clinic 2017
Pharmacy Healthcare & Communications, LLC. All Rights Reserved.